Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593103 | 0.94 | CTSK (0.40) | CTSKPKM | |
| SCHEMBL7203487 | 0.94 | CTSK (0.40) | CTSKPKM | |
| SCHEMBL5096677 | 0.85 | CTSK (0.52) | CTSKPKM | |
| SCHEMBL4687353 | 0.85 | CTSK (0.52) | CTSKPKM | |
| SCHEMBL6899315 | 0.85 | CTSK (0.41) | CTSKPKM | |
| SCHEMBL7249434 | 0.82 | CTSK (0.42) | CTSK | |
| SCHEMBL4687256 | 0.82 | CTSK (0.38) | CTSKPKM | |
| SCHEMBL5949076 | 0.77 | CTSK (0.33) | CTSKPKM | |
| SCHEMBL4686403 | 0.77 | CTSK (0.54) | CTSKPKM | |
| SCHEMBL4315397 | 0.76 | CTSK (0.38) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596715-B1 | Pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a | SMITHKLINE BEECHAM CORPORATION | 2003-07-22 | — | — | US | claimed |
| US-20070003522-A1 | Methods and compositions for improved retroviral gene and drug delivery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| US-6596715-B1 | Pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a | SMITHKLINE BEECHAM CORPORATION | 2003-07-22 | — | — | US | disclosed |